Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms

Seminars in Cancer Biology

Volumn 40_41, Issue , 2016, Pages 209-232

  Sinha, Dona ^a   Sarkar, Nivedita ^a   Biswas, Jaydip ^a   Bishayee, Anupam ^b  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b Larkin Health Science Institute   (United States)

Author keywords

Breast cancer; In vitro; In vivo; Prevention; Reseveratrol; Therapy

Indexed keywords

AROMATASE INHIBITOR; MICRORNA; PHYTOESTROGEN; RESVERATROL; ANTINEOPLASTIC AGENT; PLANT EXTRACT; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CHEMOSENSITIVITY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EVIDENCE BASED MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PLANT EXTRACTS; STILBENES;

EID: 84971463457     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.11.001     Document Type: Review

References (277)

1. [1] GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in (2012). 2012; http://globocan.iarc.fr/Default.aspx.
2. [2] Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Baiamonde, A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001), 783–792.
3. [3] Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005), 1659–1672.
4. [4] Tessari, A., Palmieri, D., di Cosimo, S., Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers. Med. 7 (2013), 1–19.
5. [5] Stenvang, J., Kümler, I., Nygård, S.B., Smith, D.H., Nielsen, D., Brünner, N., Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front. Oncol., 3, 2013, 313.
6. 2 tension measurements. Cancer Res. 51 (1991), 3316–3322.
7. [7] Hohenberger, P., Felgner, C., Haensch, W., Schlag, P.M., Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res. Treat. 48 (1998), 97–106.
8. [8] Overgaard, J., Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 25 (2007), 4066–4074.
9. [9] Bendinelli, P., Matteucci, E., Maroni, P., Desiderio, M.A., NF-κB activation,dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol. Cancer Res. 7 (2009), 1328–1341.
10. [10] Yang, H., Dou, Q.P., Targeting apoptosis pathway with natural terpenoids: implications for treatment of breast and prostate cancer. Curr. Drug Targets 11 (2010), 733–744.
11. [11] Khan, S.I., Zhao, J., Khan, I.A., Walker, L.A., Dasmahapatra, A.K., Potential utility of natural products as regulators of breast cancer-associated aromatase promoters. Reprod. Biol. Endocrinol., 9, 2011, 91.
12. [12] Bishayee, A., Ahmed, S., Brankov, N., Perloff, M., Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front. Biosci. 16 (2011), 980–996.
13. [13] Reuben, S.C., Gopalan, A., Petit, D.M., Bishayee, A., Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. Mol. Nutr. Food Res. 56 (2012), 14–29.
14. [14] Sinha, D., Biswas, J., Sung, B., Aggarwal, B.B., Bishayee, A., Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr. Drug Targets 13 (2012), 1799–1819.
15. [15] Aiyer, H.S., Warri, A.M., Woode, D.R., Hilakivi-Clarke, L., Clarke, R., Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention. J. Agric. Food Chem. 60 (2012), 5693–5708.
16. [16] Biersack, B., Schobert, R., Indole compounds against breast cancer: recent developments. Curr. Drug Targets 13 (2012), 1705–1719.
17. [17] Vadodkar, A.S., Suman, S., Lakshmanaswamy, R., Damodaran, C., Chemoprevention of breast cancer by dietary compounds. Anticancer Agents Med. Chem. 12 (2012), 1185–1202.
18. [18] Yiannakopoulou, E.C., Effect of green tea catechins on breast carcinogenesis: a systematic review of in-vitro and in-vivo experimental studies. Eur. J. Cancer Prev. 23 (2014), 84–89.
19. [19] Parikh, N.R., Mandal, A., Bhatia, D., Siveen, K.S., Sethi, G., Bishayee, A., Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives. Phytochem. Rev. 13 (2014), 793–810.
20. [20] Siddiqui, J.A., Singh, A., Chagtoo, M., Singh, N., Godbole, M.M., Chakravarti, B., Phytochemicals for breast cancer therapy: current status and future implications. Curr. Cancer Drug Targets 15 (2015), 116–135.
21. [21] Vini, R., Sreeja, S., Punica granatum and its therapeutic implications on breast carcinogenesis: a review. Biofactors 41 (2015), 78–89.
22. [22] Song, J.K., Bae, J.M., Citrus fruit intake and breast cancer risk: a quantitative systematic review. J. Breast Cancer 16 (2013), 72–76.
23. [23] Mourouti, N., Panagiotakos, D.B., Soy food consumption and breast cancer. Maturitas 76 (2013), 118–122.
24. [24] Aune, D., Chan, D.S., Vieira, A.R., Navarro Rosenblatt, D.A., Vieira, R., Greenwood, D.C., et al. Dietary compared with blood concentrations of carotenoids and breast cancer risk: a systematic review and meta-analysis of prospective studies. Am. J. Clin. Nutr. 96 (2012), 356–373.
25. [25] Ogunleye, A.A., Xue, F., Michels, K.B., Green tea consumption and breast cancer risk or recurrence: a meta-analysis. Breast Cancer Res. Treat. 119 (2010), 477–484.
26. [26] Kado, K., Forsyth, A., Patel, P.R., Schwartz, J.A., Dietary supplements and natural products in breast cancer trials. Front. Biosci. 4 (2012), 546–567.
27. [27] Catalgol, B., Batirel, S., Taga, Y., Ozer, N.K., Resveratrol: French paradox revisited. Front. Pharmacol., 3, 2012, 141.
28. [28] Mobasheri, A., Shakibaei, M., Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis. Ann. N. Y. Acad. Sci. 1290 (2013), 59–66.
29. [29] Pasinetti, G.M., Wang, J., Ho, L., Zhao, W., Dubner, L., Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. Biochim. Biophys. Acta 1852 (2014), 1202–1208.
30. [30] Borriello, A., Bencivenga, D., Caldarelli, I., Tramontano, A., Borgia, A., Zappia, V., et al. Resveratrol: from basic studies to bedside. Cancer Treat. Res. 159 (2014), 167–184.
31. [31] Aggarwal, B.B., Bhardwaj, A., Aggarwal, R.S., Seeram, N.P., Shishodia, S., Takada, Y., Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24 (2004), 2783–2840.
32. [32] Pezzuto, J.M., Resveratrol as an inhibitor of carcinogenesis. Pharm. Biol. 46 (2008), 443–573.
33. [33] Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. 2 (2009), 409–418.
34. [34] Bishayee, A., Politis, T., Darvesh, A.S., Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev. 36 (2010), 43–53.
35. [35] Carter, L.G., D'Orazio, J.A., Pearson, K.J., Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 21 (2014), R209–R225.
36. [36] Baur, J.A., Sinclair, D.A., Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5 (2006), 493–506.
37. [37] Shi, J., Zeng, Q., Liu, Y., Pan, Z., Alternaria sp. MG1, a resveratrol-producing fungus: isolation, identification, and optimal cultivation conditions for resveratrol production. Appl. Microbiol. Biotechnol. 95 (2012), 369–379.
38. [38] Wang, J., Cox, D.G., Ding, W., Huang, G., Lin, Y., Li, C., Three new resveratrol derivatives from the mangrove endophytic fungus Alternaria sp. Mar. Drugs 12 (2014), 2840–2850.
39. [39] Sanders, T.H., Mc Michael, R.W. Jr., Hendrix, K.W., Occurrence of resveratrol in edible peanuts. J. Agric. Food Chem. 48 (2000), 1243–1246.
40. [40] Burns, J., Yokota, T., Ashihara, H., Lean, M.E., Crozier, A., Plant foods and herbal sources of resveratrol. J. Agric. Food Chem. 50 (2002), 3337–3340.
41. [41] Lyons, M.M., Yu, C., Toma, R.B., Cho, S.Y., Reiboldt, W., Lee, J., et al. Resveratrol in raw and baked blueberries and bilberries. J. Agric. Food Chem. 51 (2003), 5867–5870.
42. [42] Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997), 218–220.
43. [43] Manson, M.M., Farmer, P.B., Gescher, A., Steward, W.P., Innovative agents in cancer prevention. Recent Results Cancer Res. 166 (2005), 257–275.
44. [44] Athar, M., Back, J.H., Kopelovich, L., Bickers, D.R., Kim, A.L., Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486 (2009), 95–102.
45. [45] Su, D., Cheng, Y., Liu, M., Liu, D., Cui, H., Zhang, B., Zhou, S., Yang, T., Mei, Q., Comparision of piceid and resveratrol in antioxidation and antiproliferation activities in vitro. PLoS One, 8, 2013, e54505.
46. [46] Andlauer, W., Kolb, J., Siebert, K., Furst, P., Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res. 26 (2000), 47–55.
47. [47] Soleas, G.J., Angelini, M., Grass, L., Diamandis, E.P., Goldberg, D.M., Absorption of trans-resveratrol in rats. Methods Enzymol. 335 (2001), 145–154.
48. [48] Kaldas, M.I., Walle, U.K., Walle, T., Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol. 55 (2003), 307–312.
49. [49] Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E. Jr., Walle, U.K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32 (2004), 1377–1382.
50. [50] de Santi, C., Pietrabissa, A., Spisni, R., Mosca, F., Pacifici, G.M., Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica 30 (2000), 857–866.
51. [51] Yu, C., Shin, Y.G., Chow, A., Li, Y., Kosmeder, J.W., Lee, Y.S., et al. Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19 (2002), 1907–1914.
52. [52] Goldberg, D.M., Yan, J., Soleas, G.J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36 (2003), 79–87.
53. [53] Brown, V.A., Patel, K.R., Viskaduraki, M., Crowell, J.A., Perloff, M., Booth, T.D., et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 70 (2010), 9003–9011.
54. [54] Patel, K.R., Brown, V.A., Jones, D.J., Britton, R.G., Hemingway, D., Miller, A.S., et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 70 (2010), 7392–7399.
55. [55] Riha, J., Brenner, S., Böhmdorfer, M., Giessrigl, B., Pignitter, M., Schueller, K., Thalhammer, T., Stieger, B., Somoza, V., Szekeres, T., Jäger, W., Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): impact on growth of ZR-75-1 breast cancer cells. Mol. Nutr. Food Res. 58 (2014), 1830–1842.
56. [56] van de, Wetering K., Burkon, A., Feddema, W., Bot, A., de, Jonge H., Somoza, V., et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol. 75 (2009), 876–885.
57. [57] Juan, M.E., González-Pons, E., Planas, J.M., Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J. Nutr. 140 (2010), 489–495.
58. [58] Shukla, S., Chen, Z.S., Ambudkar, S.V., Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist. Updat. 15 (2012), 70–80.
59. [59] Noguchi, K., Katayama, K., Sugimoto, Y., Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers. Med. 7 (2014), 53–64.
60. [60] Videira, M., Reis, R.L., Brito, M.A., Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochem. Biophys. Acta 1846 (2014), 312–325.
61. [61] Kim, A.L., Zhu, Y., Zhu, H., Han, L., Kopelovich, L., Bickers, D.R., et al. Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp. Dermatol. 15 (2006), 538–546.
62. [62] Athar, M., Back, J.H., Tang, X., Kim, K.H., Kopelovich, L., Bickers, D.R., et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224 (2007), 274–283.
63. [63] Bishayee, A., Darvesh, A.S., Politis, T., McGory, R., Resveratrol and liver disease: from bench to bedside and community. Liver Int. 30 (2010), 1103–1114.
64. [64] e-Asciak, C.R., Rounova, O., Hahn, S.E., Diamandis, E.P., Goldberg, D.M., Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin. Chim. Acta 246 (1996), 163–182.
65. [65] Fauconneau, B., Waffo-Teguo, P., Huguet, F., Barrier, L., Decendit, A., Merillon, J.M., Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci. 61 (1997), 2103–2110.
66. [66] Jang, D.S., Kang, B.S., Ryu, S.Y., Chang, I.M., Min, K.R., Kim, Y., Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem. Pharmacol. 57 (1999), 705–712.
67. [67] Hsieh, T.C., Wu, J.M., Resveratrol: biological and pharmaceutical properties as anticancer molecule. Biofactors 36 (2010), 360–369.
68. [68] Wang, L.X., Heredia, A., Song, H., Zhang, Z., Yu, B., Davis, C., et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J. Pharm. Sci. 93 (2004), 2448–2457.
69. [69] Lappano, R., Rosano, C., Madeo, A., Albanito, L., Plastina, P., Gabriele, B., et al. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res. 53 (2009), 845–858.
70. [70] Larrosa, M., Tomás-Barberán, F.A., Espín, J.C., Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J. Agric. Food Chem. 51 (2003), 4576–4584.
71. [71] Szewczuk, L.M., Forti, L., Stivala, L.A., Penning, T.M., Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279 (2004), 22727–22737.
72. [72] Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 1766 (2006), 63–78.
73. [73] Yager, J.D., Davidson, N.E., Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354 (2006), 270–282.
74. [74] Acconcia, F., Marino, M., The effects of 17β-estradiol in cancer are mediated by estrogen receptor signaling at the plasma membrane. Front. Physiol., 2, 2011, 30.
75. [75] Schiff, R., Massarweh, S.A., Shou, J., Bharwani, L., Arpino, G., Rimawi, M., et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother. Pharmacol. 56 (2005), 10–20.
76. [76] Hynes, N.E., Watson, C.J., Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb. Perspect. Biol., 2, 2010, 12.
77. [77] Russo, J., Hu, Y.F., Silva, I.D., Russo, I.H., Cancer risk related to mammary gland structure and development. Microsc. Res. Tech. 52 (2001), 204–223.
78. [78] Czajka-Oraniec, I., Simpson, E.R., Aromatase research and its clinical significance. Endokrynol. Pol. 61 (2010), 126–134.
79. [79] Jiao, J., Xiang, H., Liao, Q., Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer. Curr. Med. Chem. 17 (2010), 3476–3487.
80. [80] Dip, R., Lenz, S., Antignac, J.P., Le Bizec, B., Gmuender, H., Naegeli, H., Global gene expression profiles induced by phytoestrogens in human breast cancer cells. Endocr. Relat. Cancer 15 (2008), 161–173.
81. [81] Jenkins, S., Betancourt, A.M., Wang, J., Lamartiniere, C.A., Endocrine-active chemicals in mammary cancer causation and prevention. J. Steroid Biochem. Mol. Biol. 129 (2012), 191–200.
82. [82] Park, M.A., Hwang, K.A., Choi, K.C., Diverse animal models to examine potential role(s) and mechanism of endocrine disrupting chemicals on the tumor progression and prevention: do they have tumorigenic or anti-tumorigenic property. Lab. Anim. Res. 27 (2011), 265–273.
83. [83] Bhat, K.P., Lantvit, D., Christov, K., Mehta, R.G., Moon, R.C., Pezzuto, J.M., Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61 (2001), 7456–7463.
84. [84] Zhang, S., Cao, H.J., Davis, F.B., Tang, H.Y., Davis, P.J., Lin, H.Y., Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br. J. Cancer 91 (2004), 178–185.
85. [85] Le Corre, L., Fustier, P., Chalabi, N., Bignon, Y.J., Bernard-Gallon, D., Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines. Clin. Chim. Acta 344 (2004), 115–121.
86. [86] Simpson, E.R., Aromatase: biologic relevance of tissue specific expression. Semin. Reprod. Med. 22 (2004), 11–23.
87. [87] Zhao, Y., Mendelson, C.R., Simpson, E.R., Characterization of the sequences of human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stomal cells and fetal hepatocytes. Mol. Endocrinol. 9 (1995), 340–349.
88. [88] Zhao, Y., Nichols, J.E., Bulun, S.E., Mendelson, C.R., Simpson, E.R., Aromatase p450 gene expression in human adipose tissue. Role of Jak/STAT pathway in regulation of the adipose-specific promoter. J. Biol. Chem. 270 (1995), 16449–16457.
89. [89] Bulun, S.E., Lin, Z., Zhao, H., Lu, M., Amin, S., Reierstad, S., Chen, D., Regulation of aromatase expression in breast cancer tissue. Ann. N. Y. Acad. Sci. 1155 (2009), 121–131.
90. [90] Simpson, E.R., Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 86 (2003), 225–230.
91. [91] Zhou, J., Gurates, B., Yang, S., Sebastian, S., Bulun, S.E., Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res. 61 (2001), 2328–2334.
92. [92] Wang, Y., Lee, K.W., Chan, F.L., Chen, S., Leung, L.K., The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol. Sci. 92 (2006), 71–77.
93. [93] Sang, S., Yang, I., Buckley, B., Ho, C.T., Yang, C.S., Autoxidative quinone formation in vitro and metabolite formation in vivo from tea polyphenol (−)-epigallocatechin-3-gallate: studied by real-time mass spectrometry combined with tandem mass ion mapping. Free Radic. Biol. Med. 43 (2007), 362–371.
94. [94] Klaus, V., Hartmann, T., Gambini, J., Graf, P., Stahl, W., Hartwig, A., et al. 1,4-Naphthoquinones as inducers of oxidative damage and stress signaling in HaCaT human keratinocytes. Arch. Biochem. Biophys. 496 (2010), 93–100.
95. [95] Ahmad, A., Syed, F.A., Singh, S., Hadi, S.M., Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol. Lett. 159 (2005), 1–12.
96. [96] Azmi, A.S., Bhat, S.H., Hadi, S.M., Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett. 579 (2005), 3131–3135.
97. [97] Selvaraj, S., Mohan, A., Narayanan, S., Sethuraman, S., Krishnan, U.M., Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property. J. Med. Chem. 56 (2013), 970–981.
98. [98] Kovacic, P., Somanathan, R., Multifaceted approach to resveratrol bioactivity focus on antioxidant action, cell signaling and safety. Oxid. Med. Cell. Longev. 3 (2010), 86–100.
99. [99] de la Lastra, C.A., Villegas, I., Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans. 35 (2007), 1156–1160.
100. [100] Gülçin, İ., Antioxidant properties of resveratrol: a structure-activity insight. Innov. Food Sci. Emerg. Technol. 11 (2010), 210–218.
101. [101] Gambini, J., Inglés, M., Olaso, G., Lopez-Grueso, R., Bonet-Costa, V., Gimeno-Mallench, L., et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid. Med. Cell. Longev., 2015, 2015, 837042.
102. [102] Rubiolo, J.A., Mithieux, G., Vega, F.V., Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur. J. Pharmacol. 591 (2008), 66–72.
103. [103] Caoi, Z., Li, Y., Potent induction of cellular antioxidants and phase 2 enzymesby resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 489 (2004), 39–48.
104. [104] Alcendor, R.R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 100 (2007), 1512–1521.
105. [105] Olukman, M., Can, C., Erol, A., Oktem, G., Oral, O., Cinar, M.G., Reversal of doxorubicin-induced vascular dysfunction by resveratrol in rat thoracic aorta is there a possible role of nitric oxide synthase inhibition?. Anadolu Kardiyol Derg 9 (2009), 260–266.
106. [106] Dudka, J., Gieroba, R., Korga, A., Burdan, F., Matysiak, W., Jodlowska-Jedrych, B., et al. Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid. Based Complement Altern. Med., 2012, 60618.
107. [107] Lee, S.H., Kim, H.S., An, Y.S., Chang, J., Choi, J., Im, G.J., Protective effect of resveratrol against cisplatin-induced ototoxicity in HEIOC1 auditory cells. Int. J. Pediatr. Otorhinolaryngol. 79 (2015), 58–62.
108. [108] Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., Stem cells, cancer, and cancer stem cells. Nature 414 (2001), 105–111.
109. [109] Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol., 7, 2009, e1000121.
110. [110] Shafee, N., Smith, C.R., Wei, S., Kim, Y., Mills, G.B., Hortobagyi, G.N., et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68 (2008), 3243–3250.
111. [111] Hambardzumyan, D., Squatrito, M., Holland, E.C., Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10 (2006), 454–456.
112. [112] Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C., Dirks, P.B., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8 (2009), 806–823.
113. [113] Kawasaki, B.T., Hurt, E.M., Mistree, T., Farrar, W.L., Targeting cancer stem cells with phytochemicals. Mol. Interv. 8 (2008), 174–184.
114. [114] Li, Y., Wicha, M.S., Schwartz, S.J., Sun, D., Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem. 22 (2011), 799–806.
115. [115] Fulda, S., Debatin, K.M., Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 64 (2004), 337–346.
116. [116] Ito, Y., Mitani, T., Harada, N., Isayama, A., Tanimori, S., Takenaka, S., et al. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4′-amino-3,5-dihydroxy-trans-stilbenes. J. Nutr. Sci. Vitaminol. 59 (2013), 358–364.
117. [117] Li, Y., Kong, D., Wang, Z., Sarkar, F.H., Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 27 (2010), 1027–1041.
118. [118] Lançon, A., Michaille, J.J., Latruffe, N., Effects of dietary phytophenols on the expression of microRNAs involved in mammalian cell homeostasis. J. Sci. Food Agric. 93 (2013), 3155–3164.
119. [119] Phuah, N.H., Nagoor, N.H., Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed. Res. Int., 804510, 2014.
120. [120] Bove, K., Lincoln, D.W., Tsan, M.F., Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 291 (2002), 1001–1005.
121. [121] Pozo-Guisado, E., Lorenzo-Benayas, M.J., Fernández-Salguero, P.M., Resveratrol inhibited cell proliferation of MCF-7 cells by interfering with ERα associated PI3K/AKT pathway. Int. J. Cancer 109 (2004), 167–173.
122. [122] Vyas, S., Asmerom, Y., de León, D.D., Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology 146 (2005), 4224–4233.
123. [123] Vyas, S., Asmerom, Y., de León, D.D., Insulin-like growth factor II mediates resveratrol stimulatory effect on cathepsin D in breast cancer cells. Growth Factors 24 (2006), 79–87.
124. [124] Lanzilli, G., Fuggetta, M.P., Tricarico, M., Cottarelli, A., Serafino, A., Falchetti, R., et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int. J. Oncol. 28 (2006), 641–648.
125. [125] Ebert, B., Seidel, A., Lampen, A., Phytochemicals induce breast cancer resistance protein in caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol. Sci. 96 (2007), 227–236.
126. [126] Dolfini, E., Roncoroni, L., Dogliotti, E., Sala, G., Erba, E., Sacchi, N., et al. Resveratrol impairs the formation of MDA-MB-231 multicellular tumor spheroids concomitant with ceramide accumulation. Cancer Lett. 249 (2007), 143–147.
127. [127] Lubbers, J., Lewis, S., Harper, E., Hledin, M.P., Marquez, G.A., Johnson, A.E., et al. Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells. Cell Biol. Toxicol. 27 (2011), 95–105.
128. [128] de Amicis, F., Giordano, F., Vivacqua, A., Pellegrino, M., Panno, M.L., Tramontano, D., et al. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 10 (2011), 3695–3707.
129. [129] Hsieh, T.C., Wong, C., John Bennett, D., Wu, J.M., Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin αvβ3. Int. J. Cancer 129 (2011), 2732–2743.
130. [130] Gomez, L.S., Zancan, P., Marcondes, M.C., Ramos-Santos, L., Meyer-Fernandes, J.R., Sola-Penna, M., et al. Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 95 (2013), 1336–1343.
131. [131] Fu, Y., Chang, H., Peng, X., Bai, Q., Yi, L., Zhou, Y., et al. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS One, 9, 2014, e102535.
132. [132] Scarlatti, F., Sala, G., Somenzi, G., Signorelli, P., Sacchi, N., Ghidoni, R., Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 17 (2003), 2339–2341.
133. [133] Laux, M.T., Aregullin, M., Berry, J.P., Flanders, J.A., Rodriguez, E., Identification of a p53-dependent pathway in the induction of apoptosis in human breast cancer cells by the natural product, resveratrol. J. Altern. Complement. Med. 10 (2004), 235–239.
134. [134] Kim, H., Hall, P., Smith, M., Kirk, M., Prasain, J.K., Barnes, S., et al. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. J. Nutr. 134 (2004), 3445S–3452S.
135. [135] Pozo-Guisado, E., Merino, J.M., Mulero-Navarro, S., Lorenzo-Benayas, M.J., Centeno, F., Alvarez-Barrientos, A., et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-κB. Int. J. Cancer 115 (2005), 74–84.
136. [136] Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A.S., Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5 (2006), 621–629.
137. [137] Garvin, S., Ollinger, K., Dabrosin, C., Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231 (2006), 113–122.
138. [138] Li, Y., Liu, J., Liu, X., Xing, K., Wang, Y., Li, F., et al. Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl. Biochem. Biotechnol. 135 (2006), 181–192.
139. [139] Lin, H.Y., Lansing, L., Merillon, J.M., Davis, F.B., Tang, H.Y., Shih, A., et al. Integrin alphaVbeta contains a receptor site for resveratrol. FASEB J. 20 (2006), 1742–1744.
140. [140] Tang, H.Y., Shih, A., Cao, H.J., Davis, F.B., Davis, P.J., Lin, H.Y., Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5 (2006), 2034–2042.
141. [141] Sareen, D., Darjatmoko, S.R., Albert, D.M., Polans, A.S., Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharmacol. 72 (2007), 1466–1475.
142. [142] Singh, S.K., Moretta, D., Almaguel, F., Wall, N.R., de León, M., de León, D., Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 25 (2007), 363–372.
143. [143] Alkhalaf, M., Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology 80 (2007), 134–143.
144. [144] Alkhalaf, M., Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. Eur. J. Cancer Prev. 16 (2007), 334–341.
145. [145] Filomeni, G., Graziani, I., Rotilio, G., Ciriolo, M.R., Trans-resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr. 2 (2007), 295–305.
146. [146] Singh, S.K., Moretta, D., Almaguel, F., de León, M., de León, D.D., Precursor IGF-II (proIGF-II) and mature IGF-II (mIGF-II) induce Bcl-2 And Bcl-X L expression through different signaling pathways in breast cancer cells. Growth Factors 26 (2008), 92–103.
147. [147] Nguyen, T.H., Mustafa, F.B., Pervaiz, S., Ng, F.S., Lim, L.H., ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Int. J. Oncol. 33 (2008), 81–92.
148. [148] Scarlatti, F., Maffei, R., Beau, I., Codogno, P., Ghidoni, R., Role of non-canonical beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ. 15 (2008), 1318–1329.
149. [149] Sakamoto, T., Horiguchi, H., Oguma, E., Kayama, F., Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J. Nutr. Biochem. 21 (2010), 856–864.
150. [150] Shi, Y., Yang, S., Troup, S., Lu, X., Callaghan, S., Park, D.S., et al. Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol. Rep. 25 (2011), 1713–1719.
151. [151] Ferraz da Costa, D.C., Casanova, F.A., Quarti, J., Malheiros, M.S., Sanches, D., Dos Santos, P.S., et al. Transient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells. PLoS One, 7, 2012, e48746.
152. [152] Lim, K.G., Gray, A.I., Pyne, S., Pyne, N.J., Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br. J. Pharmacol. 166 (2012), 1605–1616.
153. [153] Mehdawi, H., Alkhalaf, M., Khan, I., Role of Na+/H+ exchanger in resveratrol-induced growth inhibition of human breast cancer cells. Med. Oncol. 29 (2012), 25–32.
154. [154] Khan, M.A., Chen, H.C., Wan, X.X., Tania, M., Xu, A.H., Chen, F.Z., et al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. Mol. Cells 35 (2013), 219–225.
155. [155] Aravindan, S., Natarajan, M., Herman, T.S., Awasthi, V., Aravindan, N., Molecular basis of hypoxic breast cancer cell radio sensitization: phytochemicals converge on radiation induced Rel signalling. Radiat. Oncol., 8, 2013, 4.
156. [156] Chen, F.P., Chien, M.H., Phytoestrogens induce apoptosis through a mitochondria/caspase pathway in human breast cancer cells. Climacteric 17 (2014), 385–392.
157. [157] Mohapatra, P., Satpathy, S.R., Das, D., Siddhath, S., Choudhuri, T., Kundu, C.N., Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf/Cip1 and inhibition of long patch base excision repair pathway. Toxicol. Appl. Pharmacol. 275 (2014), 221–231.
158. [158] Sprouse, A.A., Herbert, B.S., Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. Anticancer Res. 34 (2014), 5363–5374.
159. [159] Azios, N.G., Dharmawardhane, S.F., Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells. Neoplasia 7 (2005), 128–140.
160. [160] Rodrigue, C.M., Porteu, F., Navarro, N., Bruyneel, E., Bracke, M., Romeo, P.H., et al. The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities. Oncogene 24 (2005), 3274–3284.
161. [161] Azios, N.G., Krishnamoorthy, L., Harris, M., Cubano, L.A., Cammer, M., Dharmawardhane, S.F., Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. Neoplasia 9 (2007), 147–158.
162. [162] Tang, F.Y., Su, Y.C., Chen, N.C., Hsieh, H.S., Chen, K.S., Resveratrol inhibits migration and invasion of human breast-cancer cells. Mol. Nutr. Food Res. 52 (2008), 683–691.
163. [163] Tang, F.Y., Chiang, E.P., Sun, Y.C., Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. J. Nutr. Biochem. 19 (2008), 287–294.
164. [164] Lee, M.F., Pan, M.H., Chiou, Y.S., Cheng, A.C., Huang, H., Resveratrol modulates MED28 (Magicin/EG-1) expression and inhibits epidermal growth factor (EGF)-induced migration in MDA-MB-231 human breast cancer cells. J. Agric. Food Chem. 59 (2011), 11853–11861.
165. [165] Lee, H.S., Ha, A.W., Kim, W.K., Effect of resveratrol on the metastasis of 4T1 mouse breast cancercells in vitro and in vivo. Nutr. Res. Pract. 6 (2012), 294–300.
166. [166] Vergara, D., Valente, C.M., Tintelli, A., Siciliano, C., Lorusso, V., Acierno, R., et al. Resveratrol inhibits the epidermal growth factor induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 310 (2011), 1–8.
167. [167] Shi, X.P., Miao, S., Wu, Y., Zhang, W., Zhang, X.F., Ma, H.Z., et al. Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. Int. J. Mol. Sci. 14 (2013), 15655–15668.
168. [168] Bader, Y., Getoff, N., Effects of resveratrol and mixtures of resveratrol and mitomycin C on cancer cells under irradiation. Anticancer Res. 26 (2006), 4403–4408.
169. [169] Zahid, M., Gaikwad, N.W., Ali, M.F., Lu, F., Saeed, M., Yang, L., et al. Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol. Free Radic. Biol. Med. 45 (2008), 136–145.
170. [170] Lu, F., Zahid, M., Wang, C., Saeed, M., Cavaleiri, E.L., Rogan, E.G., Resveratrol prevents estrogen dependent-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev. Res. 1 (2008), 135–145.
171. [171] Beedanagari, S.R., Bebenek, I., Bui, P., Hankinson, O., Resveratrol inhibits dioxininduced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and polymerase II to the regulatory regions of the corresponding genes. Toxicol. Sci. 110 (2009), 61–67.
172. [172] Perdew, G.H., Hollingshead, B.D., Dinatale, B.C., Morales, J.L., Labrecque, M.P., Takhar, M.K., et al. Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity. J. Pharmacol. Exp. Ther. 335 (2010), 273–283.
173. [173] Macpherson, L., Matthews, J., Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells. Cancer Lett. 299 (2010), 119–129.
174. [174] Hinrichs, B., Zahid, M., Saeed, M., Ali, M.F., Cavalieri, E.L., Rogan, E.G., Formation of diethylstilbestrol-DNA adducts in human breast epithelial cells and inhibition by resveratrol. J. Steroid Biochem. Mol. Biol. 127 (2011), 276–281.
175. [175] Kang, H.J., Hong, Y.B., Kim, H.J., Wang, A., Bae, I., Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells. Toxicol. Lett. 209 (2012), 154–160.
176. [176] Leon-Galicia, I., Diaz-Chavez, J., Garcia-Villa, E., Uribe-Figueroa, L., Hidalgo-Miranda, A., Herrera, L.A., et al. Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. Eur. J. Cancer Prev. 22 (2013), 11–20.
177. [177] Chatterjee, A., Ronghe, A., Singh, B., Bhat, N.K., Chen, J., Bhat, H.K., Natural antioxidants exhibit chemopreventive characteristics through the regulation of CNC b-Zip transcription factors in estrogen-induced breast carcinogenesis. J. Biochem. Mol. Toxicol. 28 (2014), 529–538.
178. [178] Papoutsis, A.J., Lamore, S.D., Wondrak, G.T., Selmin, O.I., Romagnolo, D.F., Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J. Nutr. 140 (2010), 1607–1614.
179. [179] Papoutsis, A.J., Borg, J.L., Selmin, O.I., Romagnolo, D.F., BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. J. Nutr. Biochem. 23 (2012), 1324–1332.
180. [180] Stefanska, B., Karlic, H., Varga, F., Fabianowska-Majewska, K., Hasiberger, A., Epigenetic mechanisms in anti-cancer actions of bioactive food components—the implications in cancerprevention. Br. J. Pharmacol. 167 (2012), 279–297.
181. [181] Mirza, S., Sharma, G., Parshad, R., Gupta, S.D., Pandya, P., Ralhan, R., Expression of DNA methyl transferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J. Breast Cancer 16 (2013), 23–31.
182. [182] Osman, A.M., Bayoumi, H.M., A.I-Harthi, S.E., Damanhouri, Z.A., Elshal, M.F., Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int., 12, 2012, 47.
183. [183] Díaz-Chávez, J., Fonseca-Sánchez, M.A., Arechaga-Ocampo, E., Flores-Pérez, A., Palacios-Rodríguez, Y., Domínguez-Gómez, G., et al. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS One, 8, 2013, e64378.
184. [184] Huang, F., Wu, X.N., Chen, J., Wang, W.X., Lu, Z.F., Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells. Exp. Ther. Med. 7 (2014), 1611–1616.
185. [185] Kim, T.H., Shin, Y.J., Won, A.J., Lee, B.M., Choi, W.S., Jung, J.H., et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim. Biophys. Acta 1840 (2014), 615–625.
186. [186] Sachdeva, M., Liu, Q., Cao, J., Lu, Z., Mo, Y., Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 40 (2012), 6683–6692.
187. [187] Vislovukh, A., Kratassiouk, G., Porto, E., Gralievska, N., Beldiman, C., Pinna, G., et al. Proto-oncogenicisoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br. J. Cancer 108 (2013), 2304–2311.
188. [188] Hagiwara, K., Kosaka, N., Yoshioka, Y., Takahashi, R., Takeshita, F., Ochiya, T., Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Sci. Rep., 2, 2012, 314.
189. [189] Banerjee, S., Bueso-Ramos, C., Aggarwal, B.B., Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol:role of nuclear factor-κB, cyclooxygenase 2, and matrix mettaloproteinase 9. Cancer Res. 62 (2002), 4945–4954.
190. [190] Sato, M., Pei, R.J., Yuri, T., Danbara, N., Nakane, Y., Tsubura, A., Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett. 202 (2003), 137–145.
191. [191] Whitsett, T., Carpenter, M., Lamartiniere, C.A., Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J. Carcinog., 5, 2006, 15.
192. [192] Chatterjee, M., Das, S., Janarthan, M., Ramachandran, H.K., Chatterjee, M., Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis in rats. Eur. J. Pharmacol. 668 (2011), 99–106.
193. [193] Papoutsis, A.J., Selmin, O.I., Borg, J.L., Romagnolo, D.F., Gestational exposure to the AhR agonist 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: preventive effects of resveratrol. Mol. Carcinog. 54 (2013), 261–269.
194. [194] Singh, B., Shoulson, R., Chatterjee, A., Ronghe, A., Bhat, N.K., Dim, D.C., et al. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis 35 (2014), 1872–1880.
195. [195] Qin, W., Zhang, K., Clarke, K., Weiland, T., Sauter, E.R., Methylation and miRNA effects of resveratrol on mammary tumors versus normal tissue. Nutr. Cancer 66 (2014), 270–277.
196. [196] Pandey, P.R., Okuda, H., Watabe, M., Pai, S.K., Liu, W., Kobayashi, A., et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat. 130 (2011), 387–398.
197. [197] Pandey, P.R., Xing, F., Sharma, S., Watabe, M., Pai, S.K., Iiizumi-Gairani, M., et al. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene 32 (2013), 5111–5122.
198. [198] Castillo-Pichardo, L., Cubano, L.A., Dharmawardhane, S., Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement. Altern. Med., 13, 2013, 6.
199. [199] Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer 115 (2005), 36–45.
200. [200] Zander, S.A., Kersbergen, A., Sol, W., Gonggrijp, M., van de Wetering, K., Jonkers, J., et al. Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol. Cancer Prev. Res. 5 (2012), 1053–1060.
201. [201] Singh, C.K., George, J., Ahmad, N., Resveratrol based combinatorial strategies for cancer management. Ann. N. Y. Acad. Sci. 1290 (2013), 113–121.
202. [202] Nifli, A.P., Kampa, M., Alexaki, V.I., Notas, G., Castanas, E., Polyphenol interaction with the T47D human breast cancer cell line. J. Dairy Res. 72 (2005), 44–50.
203. [203] Schlachterman, A., Valle, F., Wall, K.M., Azios, N.G., Castillo, L., Morell, L., et al. Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transl. Oncol. 1 (2008), 19–27.
204. [204] Hsieh, T.C., Wu, J.M., Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int. J. Oncol. 33 (2008), 851–859.
205. [205] Castillo-Pichardo, L., Matrínez-Montemayor, M.M., Matrínez, J.E., Wall, K.M., Cubano, L.A., Dharmawardhane, S., Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols. Clin. Exp. Metastasis 26 (2009), 505–516.
206. [206] Cosan, D.T., Bayram, B., Soyocak, A., Basaran, A., Gunes, H.V., Degirmenci, I., et al. Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma. Cancer Biother. Radiopharm. 25 (2010), 577–580.
207. [207] Cosan, D.T., Soyocak, A., Basaran, A., Degirmenci, I., Gunes, H.V., Sahin, F.M., Effects of various agents on DNA fragmentation and telomerase enzyme activities in adenocarcinoma cell lines. Mol. Biol. Rep. 38 (2011), 2463–2469.
208. [208] Castillo-Pichardo, L., Dharmawardhane, S.F., Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr. Cancer 64 (2012), 1058–1069.
209. [209] Catania, A., Barrajón-Catalán, E., Nicolosi, S., Cicirata, F., Micol, V., Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res. Treat. 141 (2013), 55–65.
210. [210] Wesierska-Gadek, J., Kramer, M.P., Maurer, M., Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells. Food Chem. Toxicol. 46 (2008), 1327–1333.
211. [211] Singh, N., Nigam, M., Ranjan, V., Sharma, R., Balapure, A.K., Rath, S.K., Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells. J. Pharmacol. Sci. 109 (2009), 473–485.
212. [212] Fukui, M., Yamabe, N., Zhu, B.T., Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur. J. Cancer 46 (2010), 1882–1891.
213. [213] Singh, N., Nigam, M., Ranjan, V., Zaidi, D., Garg, V.K., Sharma, S., et al. Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants. Cancer Sci. 102 (2011), 1059–1067.
214. [214] Zahid, M., Saeed, M., Beseler, C., Rogan, E.G., Cavalieri, E.L., Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells. Free Radic. Biol. Med. 50 (2011), 78–85.
215. [215] He, X., Wang, Y., Zhu, J., Orloff, M., Eng, C., Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 301 (2011), 168–176.
216. [216] Casanova, F., Quarti, J., da Costa, D.C., Ramos, C.A., da Silva, J.L., Fialho, E., Resveratrol chemosensitizes breast cancer cells to melaphan by cell cycle arrest. J. Cell. Biochem. 113 (2012), 2586–2596.
217. [217] Chottanapund, S., Van Duursen, M.B., Navasumrit, P., Hunsonti, P., Timtavorn, S., Ruchirawat, M., et al. Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts. Toxicol. In Vitro 28 (2014), 1215–1221.
218. [218] Alayev, A., Berger, S.M., Kramer, M.Y., Schwartz, N.S., Holz, M.K., The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J. Cell. Biochem. 116 (2014), 450–457.
219. [219] Whitsett, T.G. Jr., Lamartiniere, C.A., Genistein and resveratrol: mammary cancer chemoprevention and mechanisms of action in the rat. Expert Rev. Anticancer Ther. 6 (2006), 1699–1706.
220. [220] Kisková, T., Ekmekcioglu, C., Garajová, M., Orendáš, P., Bojková, B., Bobrov, N., et al. A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Eur. J. Cancer Prev. 21 (2012), 163–170.
221. [221] Bobrowska-Korczak, B., Skrajnowska, D., Tokarz, A., The effect of dietary zinc and polyphenols intake on DMBA-induced mammary tumorigenesis in rats. J. Biomed. Sci., 19, 2012, 43.
222. [222] Skrajnowska, D., Bobrowska-Korczak, B., Tokarz, A., Bialek, S., Jezierska, E., Makowska, J., Copper and resveratrol attenuates serum catalase, gluatathione peroxidase, and element values in rats with DMBA-induced mammary carcinogenesis. Biol. Trace Elem. Res. 156 (2013), 271–278.
223. [223] Kisková, T., Jendželovský, R., Rentsen, E., Maier-Salamon, A., Kokošová, N., Papčová, Z., et al. Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. Eur. J. Cancer Prev. 23 (2014), 506–513.
224. [224] Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49 (2005), 472–481.
225. [225] Szekeres, T., Saiko, P., Fritzer-Szekeres, M., Djavan, B., Jager, W., Chemopreventive effects of resveratrol and resveratrol derivatives. Ann. N. Y. Acad. Sci. 1215 (2011), 89–95.
226. [226] Dias, S.J., Li, K., Rimando, A.M., Dhar, S., Mizuno, C.S., Penman, A.D., et al. Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostrate cancer xenografts. Prostrate 73 (2013), 1135–1146.
227. [227] Reen, R.K., Jamwal, D.S., Taneja, S.C., Koul, J.L., Dubey, R.K., Wiebel, F.J., et al. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochem. Pharmacol. 46 (1993), 229–238.
228. [228] Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P.S., Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64 (1998), 353–356.
229. [229] Johnson, J.J., Nihal, M., Siddiqui, I.A., Scarlett, C.O., Bailey, H.H., Mukhtar, H., et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 55 (2011), 1169–1176.
230. [230] Tsai, J.H., Hsu, L.S., Lin, C.L., Hong, H.M., Pan, M.H., Way, T.D., et al. 3, 5, 4′-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymamal transition. Toxicol. Appl. Pharmacol. 272 (2013), 746–756.
231. [231] Minutolo, F., Sala, G., Bagnacani, A., Bertini, S., Carboni, I., Placanica, G., et al. Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. J. Med. Chem. 48 (2005), 6783–6786.
232. [232] Chakraborty, A., Gupta, N., Ghosh, K., Roy, P., In vitro evaluation of the cytotoxic, anti-proliferative and anti-oxidant properties of pterostilbene isolated from Pterocarpus marsupium. Toxicol. In Vitro 24 (2010), 1215–1228.
233. [233] Pan, M.H., Lin, Y.T., Lin, C.L., Wei, C.S., Ho, C.T., Chen, W.J., Suppression of heregulin-β1/HER2-modulated invasive and aggressive phenotype of breast carcinoma by pterostilbene via inhibition of matrix metalloproteinase-9, p38 kinase cascade and Akt activation. Evid. Based Complement. Altern. Med., 2011, 2011, 562187.
234. [234] Wang, Y., Ding, L., Wang, X., Zhang, J., Han, W., Feng, L., et al. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cytoprotective autophagy in breast cancer cells. Am. J. Transl. Res. 4 (2012), 44–51.
235. [235] Ko, H.S., Kim, J.S., Cho, S.M., Lee, H.J., Ahn, K.S., Kim, S.H., et al. Urokinase-type plasminogen activator expression and Rac1/WAVE-2/Arp2/3 pathway are blocked by pterostilbeneto suppress cell migration and invasion in MDA-MB-231 cells. Bioorg. Med. Chem. Lett. 24 (2014), 1176–1179.
236. [236] Tippani, R., Prakhya, L.J., Porika, M., Sirisha, K., Abbagani, S., Thammidala, C., Pterostilbene as a potential novel telomerase inhibitor: molecular docking studies and its in vitro evaluation. Curr. Pharm. Biotechnol. 14 (2014), 1027–1035.
237. [237] Nikhil, K., Sharan, S., Singh, A.K., Chakraborty, A., Roy, P., Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ. PLoS One, 9, 2014, e104592.
238. [238] Liu, D., Kim, D.H., Park, J.M., Na, H.K., Surh, Y.J., Piceatannol inhibits phorbol ester-induced NF-kappa B activation and COX-2 expression in cultured human mammary epithelial cells. Nutr. Cancer 61 (2009), 855–863.
239. [239] Ko, H.S., Lee, H.J., Kim, S.H., Lee, E.O., Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways. J. Agric. Food Chem. 60 (2012), 4083–4089.
240. [240] Song, N.R., Hwang, M.K., Heo, Y.S., Lee, K.W., Lee, H.J., Piceatannol suppresses the metastatic potential of MCF10A human breast epithelial cells harboring mutated H-ras by inhibiting MMP-2 expression. Int. J. Mol. Med. 32 (2013), 775–784.
241. [241] Shibata, M.A., Akao, Y., Shibata, E., Nozawa, Y., Ito, T., Mishima, S., et al. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother. Pharmacol. 60 (2007), 681–691.
242. [242] Yang, L.M., Lin, S.J., Hsu, F.L., Yang, T.H., Antitumor agents. Part 3: synthesis and cytotoxicity of new trans-stilbene benzenesulfonamide derivatives. Bioorg. Med. Chem. Lett. 12 (2002), 1013–1015.
243. [243] Ma, Z., Molavi, O., Haddadi, A., Lai, R., Gossage, R.A., Lavasanifar, A., Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer Chemother. Pharmacol. 63 (2008), 27–35.
244. [244] Murias, M., Luczak, M.W., Niepsuj, A., Krajka-Kuzniak, V., Zielinska-Przyjemska, M., Jagodzinski, P.P., et al. Cytotoxic activity of 3,3′,4,4′,5,5′-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol. In Vitro 22 (2008), 1361–1370.
245. [245] Piotrowska, H., Kucinska, M., Murias, M., Expression of CYP1A1, CYP1B1 and MnSOD in a panel of human cancer cell lines. Mol. Cell. Biochem. 383 (2013), 95–102.
246. [246] Hong, Y.B., Kang, H.J., Kim, H.J., Rosen, E.M., Dakshanamurthy, S., Rondanin, R., et al. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp. Mol. Med. 41 (2009), 151–160.
247. [247] Pan, M.H., Lin, C.L., Tsai, J.H., Ho, C.T., Chen, W.J., 3, 5, 3′, 4′, 5′-Pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J. Agric. Food Chem. 58 (2010), 226–234.
248. [248] Maccario, C., Savio, M., Ferraro, D., Bianchi, L., Pizzala, R., Pretali, L., et al. The resveratrol analog 4,4′-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells. Carcinogenesis 33 (2012), 2172–2180.
249. [249] Fernández-Pérez, F., Belchí-Navarro, S., Almagro, L., Bru, R., Pedreño, M.A., Gómez-Ros, L.V., Cytotoxic effect of natural trans-resveratrol obtained from elicited Vitis vinifera cell cultures on three cancer cell lines. Plant Food Hum. Nutr. 67 (2012), 422–429.
250. [250] Madlener, S., Saiko, P., Vonach, C., Viola, K., Huttary, N., Stark, N., et al. Multifactorial anticancer effects of digalloyl resveratrol encompass apoptosis, cell cycle arrest, and inhibition of lymph endothelial gap formation in vitro. Br. J. Cancer 102 (2010), 1361–1370.
251. [251] Yenugonda, V.M., Kong, Y., Deb, T.B., Yang, Y., Riggins, R.B., Brown, M.L., Trans-resveratrol boronic acid exihibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells. Cancer Biol. Ther. 13 (2012), 925–934.
252. [252] Jeong, S.H., Song, I.S., Kim, H.K., Lee, S.R., Song, S., Suh, H., et al. An analogue of resveratrol HS-1793 exhibits anticancer activity against MCF-7 cells via inhibition of mitochondrial biogenesis gene expression. Mol. Cells 34 (2012), 357–365.
253. [253] Kim, H.J., Yang, K.M., Park, Y.S., Choi, Y.J., Yun, J.H., Son, C.H., et al. The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. Int. J. Oncol. 41 (2012), 1628–1634.
254. [254] Fujita, Y., Islam, R., Sakai, K., Kaneda, H., Kudo, K., Tamura, D., et al. Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors. Invest. New Drugs 30 (2012), 1878–1886.
255. [255] Siddiqui, A., Dandawate, P., Rub, P., Padhye, S., Aphale, S., Moghe, A., et al. Novel aza-resveratrol analogs: synthesis, characterization and anticancer activity against breast cancer cell lines. Bioorg. Med. Chem. Lett. 23 (2013), 635–640.
256. [256] Ronghe, A., Chatterjee, A., Singh, B., Dandawate, P., Murphy, L., Bhat, N.K., et al. Differential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog. J. Steroid Biochem. Mol. Biol. 144 (2014), 500–512.
257. [257] Azmi, M.N., Din, M.F., Kee, C.H., Suhaimi, M., Ping, A.K., Ahmad, K., et al. Design, synthesis and cytotoxic evaluation of o-carboxamido stilbene analogues. Int. J. Mol. Sci. 14 (2013), 23369–23389.
258. [258] Sala, M., Chimento, A., Saturnino, C., Gomez-Monterrey, I.M., Musella, S., Bertamino, A., et al. Synthesis and cytotoxic activity evaluation of 2, 3-thiazolidin-4 one derivatives on human breast cancer cell lines. Bioorg. Med. Chem. Lett. 23 (2013), 4990–4995.
259. [259] Chimento, A., Sala, M., Gomez-Monterrey, I.M., Musella, S., Bertamino, A., Caruso, A., et al. Biological activity of 3-chloro-azetidin-2-one derivatives having interesting antiproliferative activity on human breast cancer cell lines. Bioorg. Med. Chem. Lett. 23 (2013), 6401–6405.
260. [260] Kim, J.E., Kim, H.S., Shin, Y.J., Lee, C.S., Won, C., Lee, S.A., et al. LYR71, derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3 mediated matrixmetalloproteinase 9 expression. Exp. Mol. Med. 40 (2008), 514–522.
261. [261] Choi, Y.J., Yang, K.M., Kim, S.D., Yoo, Y.H., Lee, S.W., Seo, S.Y., et al. Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells. Exp. Ther. Med. 3 (2012), 592–598.
262. [262] Levi, F., Pasche, C., Lucchini, F., Ghidoni, R., Ferraroni, M., La Vecchia, C., Resveratrol and breast cancer risk. Eur. J. Cancer Prev. 14 (2005), 139–142.
263. ®). Radiat. Oncol., 7, 2012, 12.
264. [264] Zhu, W., Qin, W., Zhang, K., Rottinghaus, G.E., Chen, Y.C., Kliethermes, B., et al. Transresveratrol alters mammary promoter hypermethylation in women at increased risk of breast cancer. Nutr. Cancer 64 (2012), 393–400.
265. [265] Chow, H.H., Garland, L.L., Heckman-Stoddard, B.M., Hsu, C.H., Butler, V.D., Cordova, C.A., et al. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J. Transl. Med., 12, 2014, 223.
266. [266] Yager, J.D., Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention—a review. Steroids 99 (2015), 56–60.
267. [267] Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N., et al. Resveratrol delays age related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8 (2008), 157–168.
268. [268] Pund, S., Thakur, R., More, U., Joshi, A., Lipid bases nonemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo angiogenic efficacy. Colloids Surf. B Biointerfaces 120 (2014), 110–117.
269. [269] Kinghorn, A.D., Su, B.N., Jang, D.S., Chang, L.C., Lee, D., Gu, J.Q., et al. Natural inhibitors of carcinogenesis. Planta Med. 70 (2004), 691–705.
270. [270] Le Corre, L., Chalabi, N., Delort, L., Bignon, Y.J., Bernard-Gallon, D.J., Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol. Nutr. Food Res. 49 (2005), 462–471.
271. [271] Lee, K.W., Lee, H.J., The roles of polyphenols in cancer chemoprevention. Biofactors 26 (2006), 105–121.
272. [272] Khan, N., Afaq, F., Mukhtar, H., Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal. 10 (2008), 475–510.
273. [273] Kundu, J.K., Surh, Y.J., Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 269 (2008), 243–261.
274. [274] Dennis, T., Fanous, M., Mousa, S., Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr. Cancer 61 (2009), 587–597.
275. [275] Seehusen, D.A., Baird, D., Bode, D., Primary care of adult survivors of childhood cancer. Am. Fam. Physician 81 (2010), 1250–1255.
276. [276] Newhauser, W.D., Durante, M., Assessing the risk of second malignancies after modern radiotherapy. Nat. Rev. Cancer, 2011, 438–448.
277. [277] Tatlidede, E., Sehirli, O., Velioglu-Ogunc, A., Cetinel, S., Yegen, B.C., Yarat, A., et al. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic. Res. 43 (2009), 195–205.